Introduction
Despite some progress in therapy, chronic lymphocytic leukemia (CLL) remains incurable with standard treatments. This, coupled with the advanced age of many patients as well as the relatively indolent course of the disease in a substantial proportion of cases, makes symptom palliation a reasonable treatment goal in many cases. Nevertheless, about one-third of the patients are under the age of 60, and 10-15% are younger than 50. In this group of patients, the aim of treatment cannot merely be palliative. Young patients with poor-risk CLL requiring therapy should be offered experimental therapies aimed at achieving cure. For all these reasons, allogeneic and autologous stem cell transplantation (SCT) is increasingly considered for treatment of patients with CLL, 1 the hope being that -as with other hematological malignancies -transplants can cure a fraction of patients. The role of transplants in CLL, however, has not been established in clinical trials, and they should still be considered as experimental procedures in this disease.
In order to assess the potential therapeutic value of SCT for CLL, the present article reviews the most important clinical trials in this field, thereby attempting to answer the following crucial questions for both allo-and auto-SCT: (1) . Is SCT a curative treatment? (2) Does SCT improve the dismal prognosis of poor-risk CLL? (3) How, when, and in which subgroup of patients should SCT be performed?
As aggressive treatment modalities such as SCT should be restricted to poor-risk patients, however, the basis of considerations about CLL transplants is the definition of poor-risk disease.
Poor-risk CLL
In recent series, the median survival of patients with CLL is about 10 years. Clinical stages, degree of bone marrow infiltration, and doubling time are the most useful parameters for predicting survival. Cytogenetic abnormalities are also very important prognostic factors. 2 Thus, patients with del(13q) as a single abnormality have an excellent prognosis (median survival: 133 months), whereas those with del(11q) or del(17p) have poor survival (median survival: 79 and 32 months, respectively). In addition, serum levels of thymidin-kinase, ␤-2 microglobulin and CD23 also correlate with survival. Recently, different groups reported findings which appear of crucial importance for the understanding of the biology of CLL. 3, 4 These groups have shown that the mutational status of the Ig V gene correlates with different disease subsets. Thus, those patients with unmutated Ig V gene (type I or 'pre-germinal' CLL) have a poorer prognosis than those displaying mutated Ig V gene (type II or 'post-germinal' CLL). Of note, Ig V mutational status proved to be significant even in patients with stage A. Thus, patients with stage A deriving from naive, pre-germinal B cells had a median survival of 8 years as compared to 25 years in those cases deriving from memory B cells (P = 0.0008). 3 In initial reports, the surface expression of CD38 was reported to correlate with the Ig V gene mutational status (ie CD38 + у30% -unmutated Ig V genes; CD38 + Ͻ30% -mutated Ig V genes), however, such a relationship is not clearcut. 4, 5 The CD38 expression, however, has prognostic significance in itself.
A number of papers specifically dealing with the prognosis of young patients with CLL have been published, concluding that prognostic factors useful in overall series also discriminate different risk groups among younger patients. In a recently reported series analyzing prognostic factors in younger patients (Ͻ56 years old), lymphocyte doubling time and other disease progression features were the only significant parameters predicting survival. 6 In summary, 'poor-risk' patients are those with advanced stage (ie symptomatic disease) and additional adverse biologi-
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Leukemia cal features, such as short doubling time, high lymphocyte count, and diffuse BM infiltration pattern. In the future, 'classical' prognostic factors are likely to be complemented, if not replaced, by genetic markers such as specific cytogenetic abnormalities and Ig V mutational status, which allow identification of poor-risk patients very early in the course of the disease. As a consequence, patients with both unmutated Ig V genes and adverse interphase cytogenetics might be candidates for aggressive treatment even in asymptomatic stages.
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Autologous stem cell transplantation
To date, only four studies on autologous SCT for CLL are available which comprise sufficiently large patient numbers with informative analyses of prognostic factors to allow an approach to these three critical issues: the recent update of the CLL database of the European Group for Blood and Marrow Transplantation (EBMT), 8 the International Project on CLL Transplants, 9,10 the second interim analysis of the CLL3 study of the German CLL Study Group (to be published), and the series from Kiel.
11
Is auto-SCT a curative treatment?
As summarized in Table 1 , all of these four studies are characterized by low treatment-related mortality, on the one hand, and the lack of a plateau in the event-or relapse-free survival curves on the other hand. The fact that patients continue to relapse up to 5 years post transplant indicates that autografting does not result in the cure of CLL.
Another argument against the curative potential of auto-SCT comes from the molecular follow-up of patients from the Kiel series. Allele-specific PCR amplification of the complementary determining region 3 of the IgH gene (ASO-PCR) detected residual disease in at least two follow-up samples in 28 of 35 cases (80%) with specific CDR3 primers available, although more than half of the patients with a positive ASO-PCR had no evidence of disease by consensus primer PCR, flow cytometry, or clinical assessment. Molecular persistence or recurrence of CLL post transplant was not correlated with Binet stage. This implies that complete disease eradication was not possible by this intensive approach in the vast majority of patients even though the Kiel protocol included highly effective tools for in vivo and ex vivo CLL cell depletion and focused on individuals with early (though poor-risk) disease.
Similar findings were observed by the Barcelona group. In contrast to allogeneic transplantation, where residual disease 
Does auto-SCT improve the prognosis of patients with CLL?
A reliable evaluation of the impact of SCT on the prognosis of CLL requires prospectively randomized studies comparing autografting with conventional palliative treatment. As such studies are completely lacking to date, the possible prognostic benefit of SCT can only be roughly extrapolated from the results of the published single-arm series. These studies, however, usually suffer from patient heterogeneity and selection bias, and, thus, can hardly be compared with the generally accepted results of conventional therapy.
The most promising series of patients treated with SCT for CLL has been reported by the Dana-Farber Cancer Center. Eighty-one patients with advanced CLL underwent myeloablative therapy including total body irradiation (TBI) and cyclophosphamide followed by reinfusion of autologous BM purged with anti-B cell monoclonal antibodies and complement. There were six treatment-related deaths. With a median follow-up of about 30 months, only 14 patients have relapsed, translating into a projected 4-year disease-free survival of 63%. These figures appear to be clearly superior to any conventional second-line regimen published. [14] [15] [16] [17] In the Kiel series, we analyzed 19 patients in whom autografting was attempted as part of a second-line strategy. In these individuals, freedom from treatment failure (FFTF) post mobilization (= SCT attempt) was compared to FFTF after the last conventional regimen prior to mobilization. It became apparent that FFTF after SCT attempt was much longer than after the last standard chemotherapy (median FFTF 10 months vs not reached, P = 0.0002; Figure 1 ), implying that SCT allows more efficient tumor control than conventional treatment. Taken together, although the results of the published trials are promising, data illustrating a clear-cut therapeutic benefit of autografting in CLL are still very sparse, and the results of the ongoing prospective studies have to be awaited. 18, 19 The long-term outcome after autografting may also be influenced by late complications, in particular, secondary malignancies and infections. Due to the impaired function of the lymphoid system, there is an increased risk of viral infections particularly during the first year post transplant. 20 How-
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Figure 1
Freedom from treatment failure (FFTF) in the patients who underwent salvage SCT. Thin line, FFTF after the last conventional regimen prior to SCT attempt. Bold line, FFTF after start of highdose protocol (by intention-to-treat).
ever, infections are rarely life-threatening and thus do not have a discernible effect on overall survival. Secondary neoplasms have turned out to be a critical problem after autologous bone marrow and stem cell transplantation. Information on this particular issue in the CLL setting is sparse. In the Kiel series (n = 67), the cumulative incidence of AML/MDS is 6% (95% CI [0;16]) after 5 years and that of all secondary neoplasms 13% (95% CI [1:26] ) (unpublished data), which seems comparable to figures reported for other lymphoma. 21, 22 How, when, and in which subgroup of patients should autologous SCT be performed?
Source of stem cells:
Following the general trend in autologous transplantation, peripheral blood is becoming the main source for hematopoietic stem cells. In the EBMT series no differences have been observed between transplants performed from bone marrow and peripheral blood. 23 Fludarabine, especially in heavily pretreated patients, can jeopardize the collection of a sufficient number of peripheral blood progenitor cells. 24, 25 This has led some groups to avoid fludarabine in CLL patients to be included in transplant programs. It should be noted, however, that most patients treated with fludarabine have previously received other lines of therapya fact that negatively influences harvesting. The outcome of harvesting after front-line therapy with fludarabine should be prospectively assessed. Preliminary studies failed to demonstrate a significant impairment of stem cell collection in this situation. 26 From the practical point of view, it should be noted that an interval of no less than 3 months should be left between the last dose of fludarabine and the leukapheresis, since a shorter interval may be associated with a poor collection of hematopoietic stem cells. 24 
Conditioning regimen:
Although encouraging results have been observed after high-dose chemotherapy alone followed by autologous SCT, 27 in the vast majority of published stem cell transplants for CLL the myeloablative regimen contained total body irradiation (TBI). The rationale behind this is that CLL cells -similar to other indolent lymphatic neoplasmsare sensitive to irradiation. A recent analysis of 370 CLL autotransplants by the EBMT identified TBI as a favorable outcome predictor. 8 However, this observation might have been biased by other factors, such as the center effect. In other retrospecLeukemia tive analyses, no significant differences in outcome have been observed according to the regimen used. 9 Thus, the best preparative regimen for autografting patients with CLL is still unknown.
Purging:
Several methods of purging, such as B cell-negative selection, CD34 + -positive selection, or double selection (ie positive selection of CD34 cells followed by B cell-negative selection), are available. All of them can produce a significant degree of B cell depletion of the harvest; this could theoretically diminish the risk of relapse due to the reinfusion of tumoral cells. 15, [28] [29] [30] A possible benefit of purging has been observed in one single-center series 15 but not in registry studies, 8, 10 meaning that clear-cut evidence for the usefulness of purging of CLL autografts is still lacking. As long as cure is intended, however, we believe that autotransplantation concepts in patients with CLL should comprise effective purging of PBSC to rule out the possibility that successful disease eradication in vivo is counteracted by reinfusion of tumor cells along with the graft. 12, 20 This goal, however, might also be achieved with in vivo purging by infusion of monoclonal antibodies during the time of harvesting or autografting. 31 Purging may retard hematological and immune recovery, which is of concern when considering the already depressed immune status in CLL patients.
32-34
Timing of transplant:
Although randomized trials addressing the impact of the interval between the diagnosis and the transplant on the outcome of the procedure have not been conducted, some retrospective data suggest a better outcome for patients transplanted in an earlier phase of the disease. 8, 9 This argues in favor of transplanting patients as soon as treatment is indicated. A trial proposed by the EBMT in which patients would be randomized between immediate vs deferred transplantation might contribute to clarify this issue. On the other hand, the case could be made as to whether, rather than transplanted up front, patients should be harvested up frontonce a response is obtained, without further delay. The reason for this is that in some studies the most important limitation found with a 'deferred-transplant' policy has been the impossibility to collect enough CD34 + cells. The influence of timing and stage on the feasibility of harvesting and achievement of minimal disease prior to SCT has been addressed in the prospective Kiel and GCLLSG trials. In both series, about one-fifth of all patients considered for transplant experienced pretransplant failure, ie lack of a suitable graft or a sufficient response. A history of Binet stage C disease was the predominant factor predicting for poor pretransplant outcome, as illustrated by a failure probability of 36% and 58%, respectively, in the Kiel and CLL3 studies. 11, 19 In which subgroup of patients should autologous SCT be performed?:
In order to identify subgroups of patients who are most likely to benefit from SCT, prognostic factor analyses are needed. Possible explanatory variables predicting for the success of autografting can be divided into two groups: (1) Course-related risk factors are those which develop as the disease continues (eg stage, time from diagnosis, intensity of pretreatment, timing of transplant). Their prognostic impact may be bypassed by early transplant. (2) Biological risk factors are determined by genuine biological features of the tumor clone and cannot necessarily be eliminated by early timing of trans-
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Leukemia plant (eg disease sensitivity, lymphocyte count, doubling time, cytogenetics, mutational status).
Prognostic factor analyses are available for all four studies mentioned but must still be regarded as preliminary. Their results are listed in Table 2 . Data of 124 patients from the 'International Project on Transplants in CLL' have shown that disease status (CR or very good partial response) before transplantation was the most important prognostic factor for survival and disease-free survival (DFS). 9 Other variables correlated with a longer DFS in the univariate analysis, but not in the multivariate analysis, were the number of previous lines of therapy (р2 vs Ͼ2), response to purine analogs, degree of bone marrow infiltration pretransplant (р30% vs Ͼ30% lymphocytes) and a the interval between diagnosis and transplantation (р36 vs Ͼ36 months). Interestingly, classical prognostic factors at diagnosis such as clinical stage or degree of bone marrow involvement did not influence the outcome after transplant. This suggests that, rather than on course-related factors, the success of the transplant depends primarily on the sensitivity of the disease to treatment (which is a biological risk factor). The relationship between disease status at SCT and transplant results has also been found by the EBMT. 8 In the Kiel and GCLLSG series, respectively, preliminary analysis showed that the biological risk factors high lymphocyte counts, unmutated Ig V status (Kiel), and unfavorable cytogenetics (GCLLSG) were associated with a poor post-transplant outcome by univariate analysis (Table 2) . 35, 36 Studies of prognostic factors, however, should be interpreted with caution, given the possible positive bias among patients undergoing transplantation.
In conclusion, biological risk factors, such as disease sensitivity, lymphocyte count and adverse cytogenetics, are associated with an inferior post-transplant outcome, whereas course-related factors, such as stage and the extent of pretreatment, appear to be less important. Taking into account their preliminary character, these analyses suggest that randomized trials on SCT might be best performed in a salvage setting, since the results of conventional second-line treatment in CLL are poor, whereas the outcome after autografting is encouraging and does not appear to be very different between patients with early and advanced disease, respectively. Thus, the possible benefits of SCT will emerge more easily and rapidly if studied as second-line treatment. Whether this, on the other side, questions the justification of further trials on early transplant remains highly debatable. Almost every patient with poor-risk features will progress to a symptomatic stage and, Table 2 Prognostic factor analysis for post-transplant outcome in autologous SCT in CLL ultimately, fulfill the criteria for SCT. Delaying high-dose therapy until advanced stage or need for salvage treatment, however, implies that many patients will never receive an autograft due to mobilization failure and resistant disease.
Allogeneic stem cell transplantation
Allogeneic SCT is a treatment approach which is fundamentally different from autologous transplantation, in particular in the context of indolent diseases such as CLL. Whereas efficacy (and complications) of autografting rely exclusively on the cytotoxic therapy administered, the crucial antileukemic principle of allotransplantation appears to be the immunemediated anti-host activities conferred with the graft (GVL effects). Accordingly, autologous SCT adds nothing else than intensity (and perhaps a radiotherapeutic component) to conventional treatment. For this reason, the mortality of autotransplantation is nowadays only slightly higher than that of intensive conventional chemotherapeutic regimens, but its capacity for complete eradication of resistant CLL clones seems to be limited, too. On the other hand, allogeneic transplantation introduces the entirely different modality of cellular immune therapy, which appears to be responsible for its superior antileukemic activity as well as for its considerably higher toxicity.
Is allo-SCT a curative treatment?
Three registry series on allogeneic SCT for CLL have been published and are summarized in Table 3 . In general, allo-SCT in CLL is characterized by a high treatment-related mortality (TRM) on the one hand and a very low relapse incidence on the other hand. 13, 23, [37] [38] [39] [40] In most studies, the survival curves appear to approach a plateau in the long term, suggesting that allotransplantation may have curative potential in this disease. Moreover, allogeneic transplants can induce sustained complete responses in patients refractory to treatment, including cases resistant to purine analogs; this is again in contrast to results in autologous transplants in which sensitivity of the disease to treatment is a necessary pre-requisite for the success of the procedure. The superior tumor control provided by allografting in comparison to autografting suggests a pronounced susceptibility of CLL to GVL effects.
Another line of evidence for the presence of GVL activity and, thus, curative potential of allografting in CLL comes from the documented efficacy of donor lymphocyte infusions and the fact that CLL cells persisting after dose-reduced conditioning for allogeneic SCT disappear with the onset of chronic graft-versus-host disease.
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Does allo-SCT improve the prognosis of patients with CLL?
In spite of the low relapse rate, survival after allo-SCT is significantly lower than after autologous SCT, at least during the first 4 years. The reason for this is the high toxicity associated with allografting for this particular indication. Even in experienced centers, the TRM of allogeneic SCT in patients with CLL is reported to be up to 50% (Table 3 ). The causes of these detrimental results are not completely clear, but patient age, selection of poor-risk patients with advanced disease and extensive pretreatment, and the CLL-associated incompetence of the immune system may all contribute to the high TRM observed. The recent development of conditioning regimens with reduced intensity may help to improve the tolerability of allo-SCT in CLL without affecting its GVL activities.
How, when, and in which subgroup of patients should allogeneic SCT be performed? Source of stem cells:
The majority of allotransplants have been performed using a family donor. The experience with allogeneic transplantation from unrelated donors (UD) is very limited. In a recent report, Pavletic et al 49 analyzed the results of transplants from UD in 40 patients with CLL reported to the 'National Marrow Donor Program'. The median age was 44 years, ranging from 26 to 57. Twenty patients (50%) were chemorefractory, and 32 (80%) received prior fludarabine. Estimated day 100 survival was 67%. The incidence of grades III-IV acute GVHD was 28%, and extensive chronic GVHD 35%. Out of 33 evaluable patients, 21 (64%) achieved CR and five (15%) PR. The cumulative 3-year incidence of relapse was 13% (95% CI [1;25] ). For 33 patients with available relapse data 3-year disease-free survival was 44% (95% CI [26;62] ). Eighteen patients are alive with a median follow-up of 3 years (range: 0.3-5.1 years). The median survival was 1.8 years and estimated overall survival at 3 years was 41% (95% CI [24;58] ). Although this is a highly selected series, these data are encouraging and suggest that younger patients with refractory disease for whom a family donor is not available might benefit from UD transplant.
Although bone marrow remains the main source, peripheral blood is increasingly being used to obtain stem cells. No comLeukemia parative studies of results with bone marrow vs peripheral blood allotransplants have been reported.
Conditioning regimens and non-myeloablative stem cell transplants:
In most centers, standard TBI/cyclophosphamide has been used as conditioning regimen. It should be noted, on the other hand, that since the GVL effect appears to be very active in CLL, the intensity of the conditioning regimen may not be as important as in other diseases. Given this fact on the one hand and the extremely high TRM associated with standard myeloblative conditioning on the other hand, the use of non-myeloablative regimens is particularly appealing in CLL.
The German CLL Study Group has conducted a pilot study using a non-myeloablative conditioning regimen consisting of a combination of fludarabine and cyclophosphamide. Seven patients with symptomatic CLL relapsing after fludarabine or equivalent high-risk features were eligible. GVHD prophylaxis was performed with CsA/short-course MTX or CsA/MMF. PBSC were obtained from HLA-identical donors. As assessed by XY-FISH or STR-PCR, Ͼ95% hematopoietic donor chimerism was achieved in all patients (in two only after DLI). Median time to Ͼ95% chimerism was 108 (49-202) days. Early non-hematological toxicity was very low. Five patients experienced acute and/or chronic GVHD; in four cases, chronic GVHD was associated with immunologic and molecular clearance of residual disease surviving conditioning chemotherapy. With 12 (9-24) months of follow-up, all patients are alive and progression-free. 45 Similarly promising findings were observed in other single-center series. 44, 46, 47 The EBMT Chronic Leukemia Working Party collected data on 63 patients who had undergone allogeneic SCT for CLL using dose-reduced conditioning. 48 The conditioning regimen consisted of low-dose TBI in only 10%, of a combination of fludarabine and TBI in 13%, and of a combination of fludarabine and alkylating agents in 69% of the cases, respectively. The median number of previous chemotherapy regimens was three (0-8). Seventy-seven percent of the patients had received fludarabine prior to transplant. A complete or partial remission (PR) at SCT was present in 60% of patients, whereas 40% had less than PR. ECOG performance was good (0-1) in 82% of patients. In all cases, HLA-identical donors were used (siblings 81%; unrelated 19%). Cumulative TRM was 19% (95% CI [7;30] ) after 12 months. Acute GVHD grade II-IV occurred in 32% of patients, whereas the 12-month cumulative incidence of chronic GVHD was 75%. With a median follow-up of 8 (1-30) months, event-free and overall survival (OS) at 12 months were 69% (95% CI [56;82]) and 80% (95% CI [68;91]), respectively. The 12 month probability of relapse SPOTLIGHT Leukemia or progression was 16%, with no event occurring later than 4 months post transplant.
Thus, dose-reduced conditioning appears to favorably influence the outcome after allogeneic SCT for CLL by reducing TRM while preserving GVL activity and seems to be a very promising approach for patients with poor-risk CLL.
Timing of transplant and patient selection:
Conclusive prognostic factor analyses for identifying subgroups of patients who are most likely to benefit from allogeneic SCT for CLL are not available to date. However, given the high or uncertain TRM still associated with allografting, at the present time allo-SCT in CLL should be restricted to symptomatic patients with very high-risk disease, such as those refractory to treatment, in early relapse after autotransplantation or other unfavorable features such as unfavorable cytogenetics or unmutated IgVH genes. In these subgroups, the considerable risk of TRM should be more than outweighed by the prognostic improvement due to the effective disease control provided by allogeneic SCT.
Conclusions and perspectives
Autologous and allogeneic stem cell transplantation appear to be fundamentally different treatment modalities for patients with CLL. The efficacy of autografting relies exclusively on the cytotoxic therapy administered. With appropriate supportive care, it is safe and can induce long-lasting clinical and molecular remissions. Feasibility of autologous SCT appears to be best early during the course of the disease, but there is only limited hope that autotransplantation can cure the disease even in this favorable subgroup. Nevertheless, the results of the published series suggest that auto-SCT is capable of improving the prognosis of CLL with defined poor-risk features. Since post-transplant outcome does not appear to be very different between patients with first-line and salvage SCT, respectively, randomized trials on auto-SCT might be best performed in a salvage setting, where the results of conventional second-line treatment in CLL are poor, and thus, the possible benefits of SCT will emerge more easily and rapidly. Such a trial has recently started as a combined effort of the EBMT and several European national groups. Given the excellent feasibility of auto-SCT in early (but not in advanced) stages, further refinement of the procedure towards cure by implementing additional modalities, such as monoclonal antibodies, should focus on early patients with biological poor-risk features, such as adverse chromosomal abnormalities and unmutated Ig V H genes. The recently launched CLL3C trial of the GCLLSG tries to explore this strategy by adding CAMPATH-1H to the myeloablative regimen.
The crucial antileukemic principle of allotransplantation consists of the immune-mediated GVL effects conferred with the graft. The GVL activity should be responsible for the better disease control observed after allografting which seems to be a curative treatment for at least a subset of poor-risk patients. However, as long as allo-SCT in CLL is still associated with an excessively high TRM, only selected patients with advanced poor-risk disease and low probability of successful auto-SCT should be considered for allografting. The development of conditioning regimens with reduced intensity may allow extension of the indications of allogeneic SCT for CLL in the near future. To this end, the German CLL Study Group runs the EBMT-approved CLL3X trial, which studies the fludarabine-based conditioning regimen in patients with very highrisk disease. Other groups are currently undertaking similar projects.
Taken together, autologous transplantation is preferable for patients with early or sensitive disease. Selected patients with advanced poor-risk disease and low probability of successful auto-SCT should be considered for allografting. However, it must be kept in mind that both autologous and allogeneic stem cell transplantation are still experimental procedures which should not be performed outside of approved clinical trials.
